AFP News, November 11, 2025: France 24 explains FDA decision to delete most black box warnings for hormone therapy for menopause, despite controversies about the risks. NCHR’s Diana Zuckerman says warnings needed to be updated but hormones have serious risks and limited benefits.
Read More »We’re In The News
As a respected nonprofit health research center, our views are often quoted in the media, including newspapers, magazines, TV, radio, and websites. We also write articles and blogs for a number of different and highly respected newspapers, magazines, and popular websites, and we are published in prestigious medical journals and health policy publications. We frequently express our policy views in letters to government officials and public comments to federal agencies and we sometimes release statements or press releases on newsworthy issues.
Please e-mail info@center4research.org or call 202-223-4000 with your inquiries. We can assist you with scheduling interviews with the NCHR President, Dr. Diana Zuckerman, and other experts on our staff.
Politico Prescription Plus: FDA Removes Black Box HRT Warning
Politico, November 11, 2025: FDA Commissioner Marty Makary announces that FDA seeks eliminating most black box warnings from hormone therapy for menopause and accuses “dogma” that scared women. NCHR Diana Zuckerman said risks of cancer and heart disease are well established and claims of incomparable benefits are PR rather than science.
Read More »The FDA removes long-standing warning from hormone-based menopause drugs
AP News, November 10, 2025: AP explains FDA decision to
delete most black box warnings for hormone therapy for menopause,
despite controversies about the risks. NCHR’s Diana Zuckerman
says FDA lost credibility for deleting such important warnings without
scientific review using FDA Advisory Committee.
F.D.A. Will Remove Black Box Warnings From Hormone Treatments for Menopause
The New York Times, November 10, 2025: This NYT article describes the different data and opinions regarding FDA Commissioner Makary’s decision to remove the black box from all hormone therapy products for menopause despite risks of cancer and stroke. NCHR president Dr. Diana Zuckerman explains why this is a step backward for women’s health.
Read More »FDA ‘serious’ about hormone therapy changes
Politico, October 28, 2025: Politico predicts FDA will revise black box warnings on hormones for menopause, but it isn’t clear how. NCHR’s Diana Zuckerman explains warnings are needed but require more nuance because the evidence is different for hormone creams compared to pills, and evidence of risks and benefits for pills depend on factors such as the type of hormones and the age, medical history, and other differences in the women.
Read More »